Denali Therapeutics (NASDAQ:DNLI) Coverage Initiated by Analysts at Deutsche Bank Aktiengesellschaft

Stock analysts at Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report issued on Tuesday,Briefing.com Automated Import reports. The firm set a “buy” rating and a $31.00 price target on the stock. Deutsche Bank Aktiengesellschaft’s target price indicates a potential upside of 48.47% from the stock’s current price.

A number of other brokerages have also recently commented on DNLI. HC Wainwright lowered their target price on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. JPMorgan Chase & Co. lowered their target price on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a report on Tuesday, January 7th. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a report on Wednesday, January 15th. Finally, Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a research note on Monday, December 16th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $37.42.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock opened at $20.88 on Tuesday. The business has a 50-day moving average of $22.10 and a 200 day moving average of $24.82. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.33. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -7.57 and a beta of 1.43.

Insider Transactions at Denali Therapeutics

In other news, Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the sale, the director now owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve E. Krognes sold 3,339 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the sale, the director now directly owns 25,757 shares in the company, valued at $536,003.17. This trade represents a 11.48 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 47,940 shares of company stock valued at $973,442. Corporate insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC increased its position in Denali Therapeutics by 60.4% during the fourth quarter. Intech Investment Management LLC now owns 47,401 shares of the company’s stock worth $966,000 after buying an additional 17,858 shares during the period. Cibc World Markets Corp acquired a new position in Denali Therapeutics during the fourth quarter worth approximately $237,000. Swiss National Bank increased its position in Denali Therapeutics by 1.1% during the fourth quarter. Swiss National Bank now owns 253,500 shares of the company’s stock worth $5,166,000 after buying an additional 2,800 shares during the period. Wealthfront Advisers LLC acquired a new position in Denali Therapeutics during the fourth quarter worth approximately $403,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Denali Therapeutics by 33.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,757 shares of the company’s stock valued at $810,000 after purchasing an additional 10,038 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.